Infliximab with azathioprine for children with Crohn's disease
Part of Digestive system clinical trials.
This study tests whether combining infliximab (a biologic medicine that reduces inflammation) with azathioprine (an immune-suppressing drug) is safe and effective for children with moderate to severe Crohn's disease who haven't tried these medicines before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has Crohn's disease that is moderate to severe, with a score of 30 or higher on the Pediatric Crohn's Disease Activity Index.
- Your child has not been treated with azathioprine, 6-mercaptopurine, or infliximab before.
- Steroid medicines (like prednisone) must be stopped at least 2 weeks before starting the trial.
- Your child does not have other serious conditions like tuberculosis, hepatitis B or C, HIV, short bowel syndrome, or a narrowed intestine.
- Your child does not have certain genetic changes that affect how the body processes some medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a specific gut bacteria (Akkermansia muciniphila) to the standard Crohn's treatment infliximab helps heal the intestinal lining better. This could improve long-term control of Crohn's disease.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This study tests if a special diet (called CDED) combined with infliximab (a biologic drug) is more effective than infliximab alone for children with newly diagnosed or relapsed moderate-to-severe Crohn’s disease. It aims to improve gut healing and reduce inflammation.
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new Crohn's Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.